Bobak R. Azamian Sells 3,904 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 3,904 shares of Tarsus Pharmaceuticals stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $15.11, for a total transaction of $58,989.44. Following the transaction, the chief executive officer now owns 1,124,613 shares of the company’s stock, valued at approximately $16,992,902.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tarsus Pharmaceuticals Trading Down 0.2 %

Shares of TARS opened at $14.54 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 16.40 and a current ratio of 16.40. The company has a 50-day moving average of $15.84 and a two-hundred day moving average of $16.05. Tarsus Pharmaceuticals, Inc. has a 12-month low of $10.80 and a 12-month high of $21.47.

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last issued its quarterly earnings results on Wednesday, November 9th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.14. Tarsus Pharmaceuticals had a negative net margin of 324.99% and a negative return on equity of 34.24%. As a group, equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of TARS. Dimensional Fund Advisors LP grew its holdings in shares of Tarsus Pharmaceuticals by 221.0% during the first quarter. Dimensional Fund Advisors LP now owns 28,855 shares of the company’s stock worth $485,000 after buying an additional 19,865 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Tarsus Pharmaceuticals by 3.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock valued at $818,000 after purchasing an additional 1,402 shares during the period. UBS Group AG grew its holdings in Tarsus Pharmaceuticals by 37.0% in the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after purchasing an additional 1,142 shares during the period. Invesco Ltd. grew its holdings in Tarsus Pharmaceuticals by 17.1% in the first quarter. Invesco Ltd. now owns 27,982 shares of the company’s stock valued at $471,000 after purchasing an additional 4,078 shares during the period. Finally, State Street Corp grew its holdings in Tarsus Pharmaceuticals by 2.4% in the first quarter. State Street Corp now owns 132,883 shares of the company’s stock valued at $2,235,000 after purchasing an additional 3,141 shares during the period. 76.82% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Oppenheimer cut their target price on shares of Tarsus Pharmaceuticals from $66.00 to $43.00 in a research report on Thursday, November 10th.

Tarsus Pharmaceuticals Company Profile

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.